Abstracts

Real-world delivery, toxicity and outcomes of perioperative FLOT chemotherapy in resectable gastric/gastroesophageal adenocarcinoma: A population-based study

Background Perioperative docetaxel, oxaliplatin and fluorouracil/leucovorin (FLOT) has become the new standard of care for resectable gastric/ gastroesophageal adenocarc...

06/27/2022

Trastuzumab deruxtecan showed similar clinical benefit for frail HER2 positive gastric cancer patients: Retrospective observational study

Background Trastuzumab deruxtecan(T-DXd) showed promising effect for HER2 positive advanced gastric cancer (AGC) patients who previously received two or more chemotherap...

06/27/2022

Simple endoscopic scoring of patients with rectal cancer after concurrent chemoradiation therapy

Background Neoadjuvant concurrent chemoradiotherapy (CCRT) is an effective treatment option for patients with rectal cancer. In this study, we investigated the clinical ...

06/27/2022

Patient preferences for unresectable hepatocellular carcinoma (HCC) treatments: Balancing overall survival and quality of life

Background Atezolizumab plus bevacizumab has become the new standard-of-care treatment option for unresectable HCC, replacing oral tyrosine kinase inhibitors (e.g., sora...

06/27/2022

Phase 1b study of RGX-202-01, a first-in-class oral inhibitor of the SLC6A8/CKB pathway, in combination with FOLFIRI and bevacizumab (BEV) in second-line advanced colorectal cancer (CRC)

Background A proprietary in vivo target discovery screen identified creatine kinase-B (CKB) as a cancer driver in KRAS mutant (KRAS-mut) CRC. CKB promotes tumor growth a...

06/27/2022

Clustering analysis identified three IDH1-mutated intrahepatic cholangiocarcinoma's clusters with prognostic significance

Background IDH1-mutated intrahepatic cholangiocarcinomas (IDH1-m iCCAs), due to the therapeutic implications with anti-IDH1 drugs. A deeper insight into the molecular he...

06/27/2022

Multi-institutional analysis of real-world activity and safety of trifluridine/tipiracil plus bevacizumab in patients with refractory metastatic colorectal cancer

Background Trifluridine/tipiracil (TAS-102) plus bevacizumab (BEV) was compared with TAS-102 monotherapy in a randomized, open-label, phase 2 trial, and produced a stati...

T. Troiani ;

P. Incoronato ;

Ralph J. Napolitano Jr., DPM, CWSP, FACFAS;

V. Nacca ;

F. Paragliola ;

G. Suarato ;

A. Nicastro ;

A. Perrone ;

Erika Martinelli , MD, PhD;

G. Arrichiello ;

06/27/2022

Pathologic complete response to neoadjuvant chemoradiation as a predictor of survival in Latin American patients with rectal cancer

Background Curative surgery after neoadjuvant chemoradiotherapy is the gold-standard treatment of patients with locally advanced rectal cancer. Pathologic complete respo...

06/27/2022

Evaluation of HER2 status in equivocal gastric cancer tissue samples using surrogate DNA methylation markers

Background Her2 (ERBB2) proto-oncogene amplification and overexpression are observed in 20-30% of gastric cancer (GC) patients and play a crucial role in invasive GC dev...

06/27/2022

Latin American population with adenocarcinoma of the esophagogastric junction: A 9-year follow up

Background Esophagogastric junction (EGJ) adenocarcinoma represents 27% of gastric tumors with an increasing incidence in Western countries. Additionally, up to 80% of E...

06/27/2022